Clinical trials: asthma
Asthma
A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)
To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate asthma patients to permit further clinical investigation.
- Trial name
- NCT00646789
- Testing
- Comparator: MK0633
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers
This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma.
- Trial name
- NCT00411814
- Testing
- GSK679586
- Where
- 2 sites in Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)
The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
- Trial name
- NCT07780643
- Testing
- GSK5784283, Standard of care
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Asthma
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma
The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.
- Trial name
- NCT01018550
- Testing
- AMG 853
- Volunteers
- 397 people
- Sponsor
- Amgen
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
Asthma
FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.
- Trial name
- NCT00370097
- Testing
- FLOVENT (fluticasone propionate) HFA
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
This study has the objective of providing compassionate use access to omalizumab (Xolair) and to evaluate the Safety of Xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to…
- Trial name
- NCT00639691
- Testing
- omalizumab
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Novartis
Moderate to Severe Persistent Asthma
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
- Trial name
- NCT04773678
- Testing
- CBP-201
- Where
- 76 sites in United States, China and 3 more
- Volunteers
- 322 people
- Sponsor
- Connect Biopharm LLC
Asthma
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not…
- Trial name
- NCT01436071
- Testing
- Fluticasone furoate 50mcg
- Where
- 24 sites in United States, Mexico and 2 more
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603278
- Testing
- GW685698X
- Where
- 155 sites in United States, Canada and 11 more
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchospasm
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of…
- Trial name
- NCT01174732
- Testing
- albuterol inhalation powder, albuterol inhalation aerosol
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence
The purpose of this Study is to assess the effect of a smartphone application connected to an add-on device system fitted on Pressured Metered Dose Inhaler (PMDI) on adherence to take medications as prescribed and clinical…
- Trial name
- ADVICE (NCT03951714)
- Testing
- Marketed experience application on adherence
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
This study incorporates objectives directed at two subject cohorts: 1. Uncontrolled Adult and Pediatric Asthma Subjects: To demonstrate a statistically significant and clinically meaningful decline in Point Of Care (POC) FeNO as…
- Trial name
- NCT07228026
- Testing
- fenoTRACK Device
- Where
- 13 sites in United States
- Volunteers
- 160 people
- Sponsor
- Biometry Inc
Chronic Obstructive Pulmonary Disease (COPD)
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference…
- Trial name
- NCT01634620
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Aerocrine AB
Asthma
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus
The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream.
- Trial name
- NCT01766843
- Testing
- Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
This study planned to assess the effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist…
- Trial name
- NCT02336425
- Testing
- QGE031
- Where
- 37 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A 24-week rPMS Study in Real-world Setting for Enerzair
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Enerzair inhalation capsule for up to 24 weeks under…
- Trial name
- NCT05274425
- Testing
- Enerzair 150/50/80 μg, Enerzair 150/50/160 μg
- Where
- 21 sites in South Korea
- Volunteers
- 683 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Allergic Rhinitis
Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
The purpose of this study is to assess real-world effectiveness of montelukast in children (2 to 14 years) with asthma and allergic rhinitis.
- Trial name
- NCT00442559
- Testing
- montelukast sodium, inhaled corticosteroid
- Volunteers
- 191 people
- Sponsor
- Organon and Co
Asthma
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic…
- Trial name
- AGILE (NCT05243680)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 137 sites in United States, Australia and 12 more
- Volunteers
- 641 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.